236 related articles for article (PubMed ID: 15734995)
1. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients.
Fiegl H; Millinger S; Mueller-Holzner E; Marth C; Ensinger C; Berger A; Klocker H; Goebel G; Widschwendter M
Cancer Res; 2005 Feb; 65(4):1141-5. PubMed ID: 15734995
[TBL] [Abstract][Full Text] [Related]
2. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation in serum of breast cancer patients: an independent prognostic marker.
Müller HM; Widschwendter A; Fiegl H; Ivarsson L; Goebel G; Perkmann E; Marth C; Widschwendter M
Cancer Res; 2003 Nov; 63(22):7641-5. PubMed ID: 14633683
[TBL] [Abstract][Full Text] [Related]
4. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer.
Fiegl H; Jones A; Hauser-Kronberger C; Hutarew G; Reitsamer R; Jones RL; Dowsett M; Mueller-Holzner E; Windbichler G; Daxenbichler G; Goebel G; Ensinger C; Jacobs I; Widschwendter M
Clin Cancer Res; 2008 Jun; 14(11):3494-502. PubMed ID: 18519782
[TBL] [Abstract][Full Text] [Related]
5. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
6. Prognostic DNA methylation marker in serum of cancer patients.
Müller HM; Fiegl H; Widschwendter A; Widschwendter M
Ann N Y Acad Sci; 2004 Jun; 1022():44-9. PubMed ID: 15251938
[TBL] [Abstract][Full Text] [Related]
7. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Martens JW; Nimmrich I; Koenig T; Look MP; Harbeck N; Model F; Kluth A; Bolt-de Vries J; Sieuwerts AM; Portengen H; Meijer-Van Gelder ME; Piepenbrock C; Olek A; Höfler H; Kiechle M; Klijn JG; Schmitt M; Maier S; Foekens JA
Cancer Res; 2005 May; 65(10):4101-17. PubMed ID: 15899800
[TBL] [Abstract][Full Text] [Related]
8. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence.
Herbst A; Wallner M; Rahmig K; Stieber P; Crispin A; Lamerz R; Kolligs FT
Eur J Gastroenterol Hepatol; 2009 May; 21(5):565-9. PubMed ID: 19282772
[TBL] [Abstract][Full Text] [Related]
9. Methylation of serum DNA is an independent prognostic marker in colorectal cancer.
Wallner M; Herbst A; Behrens A; Crispin A; Stieber P; Göke B; Lamerz R; Kolligs FT
Clin Cancer Res; 2006 Dec; 12(24):7347-52. PubMed ID: 17189406
[TBL] [Abstract][Full Text] [Related]
10. Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer.
Deligezer U; Eralp Y; Akisik EZ; Akisik EE; Saip P; Topuz E; Dalay N
Ann N Y Acad Sci; 2008 Aug; 1137():175-9. PubMed ID: 18837944
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients.
Göbel G; Auer D; Gaugg I; Schneitter A; Lesche R; Müller-Holzner E; Marth C; Daxenbichler G
Breast Cancer Res Treat; 2011 Nov; 130(1):109-17. PubMed ID: 21221769
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
13. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA
Breast Cancer Res Treat; 2009 Jul; 116(2):303-9. PubMed ID: 18821012
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
15. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
[TBL] [Abstract][Full Text] [Related]
18. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
[TBL] [Abstract][Full Text] [Related]
19. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
20. Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?
Peppercorn J; A Carey L
Expert Rev Anticancer Ther; 2008 Feb; 8(2):191-4. PubMed ID: 18279059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
